Molecular genetic analysis of quinolone resistance-determining region of DNA Gyrase-A in fluoroquinolones resistant Klebsiella pneumoniae based on GenBank data and reported studies

Molecular Genetics, Microbiology and Virology

Volumn 29, Issue 4, 2014, Pages 211-215

  Heiat, M ^a   Rezaeimehr, M R ^b   Moghaddam, M M ^a   Ranjbar, R ^a   Najafi, A ^a  

^a BAQIYATALLAH UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b JAHROM UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

fluoroqinolone resistant; gyrA gene; Klebsiella pneumoniae; mutation

Indexed keywords

DNA TOPOISOMERASE (ATP HYDROLYSING) A; QUINOLONE;

AMINO ACID SUBSTITUTION; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL GENETICS; BACTERIAL STRAIN; BINDING AFFINITY; ENZYME BINDING; FLUOROQUINOLONE RESISTANT KLEBSIELLA PNEUMONIAE; GENBANK; GENE FREQUENCY; GYRA GENE; HYDROPHOBICITY; KLEBSIELLA PNEUMONIAE; MOLECULAR GENETICS; MUTATION RATE; MUTATIONAL ANALYSIS; NONHUMAN; NUCLEOTIDE SEQUENCE; SEQUENCE ALIGNMENT; SEQUENCE ANALYSIS; SPONTANEOUS MUTATION;

BACTERIA (MICROORGANISMS); KLEBSIELLA PNEUMONIAE;

EID: 84946894148     PISSN: 08914168     EISSN: 1934841X     Source Type: Journal    
DOI: 10.3103/S0891416814040041     Document Type: Article

References (34)

1. Fiegel, J., Clarke, R., and Edwards, D.A., Airborne infectious disease and the suppression of pulmonary bioaerosols, Drug Discovery Today, 2006, vol. 11, no. 1, pp. 51–57.
2. Ryan, K.J. and Ray, C.G., Sherris Medical Microbiology, New York: McGraw Hill Med., 2010.
3. Zhao, F., Bai, J., Wu, J., Liu, J., Zhou, M., Xia, S., Wang, S., Yao, X., Yi, H., and Lin, M., Sequencing and genetic variation of multidrug resistance plasmids in Klebsiella pneumoniae, PloS One, 2010, vol. 5, no. 4, p. e10141.
4. Behzadi, P. and Behzadi, E., The microbial agents of urinary tract infections at Central Laboratory of Dr. Shariati Hospital, Tehran, Iran, Turk. Klin. J. Med. Sci., 2008, vol. 28, no. 4, p. 445.
5. Behzadi, P., Behzadi, E., Yazdanbod, H., Aghapour, R., Cheshmeh, M.A., and Omran, D.S., A survey on urinary tract infections associated with the three most common uropathogenic bacteria, Maedica, 2010, vol. 5, no. 2, p. 111.
6. Chuang, Y.-P., Fang, C.-T., Lai, S.-Y., Chang, S.-C., and Wang, J.-T., Genetic determinants of capsular serotype K1 of Klebsiella pneumoniae causing primary pyogenic liver abscess, J. Infect. Dis., 2006, vol. 193, no. 5, pp. 645–654.
7. Hirsch, E.B., and Tam, V.H., Detection and treatment options for Klebsiella pneumoniae carbapenemases (KPCs): an emerging cause of multidrug-resistant infection, J. Antimicrob. Chemother., 2010, vol. 65, no. 6, pp. 1119–1125.
8. Poirel, L., Ros, A., Carricajo, A., Berthelot, P., Pozzetto, B., Bernabeu, S., and Nordmann, P., Extremely drug-resistant Citrobacter freundii isolate producing NDM-1 and other carbapenemases identified in a patient returning from India, Antimicrob. Agents Chemother., 2011, vol. 55, no. 1, pp. 447–448.
9. Suddhasattya, D., Himansu, B.S., Dhiraj, K., Vaidanathanan, S., Ratnakar, C.H., Subhasis, M., Ansuman, P., and Bharat, K.D., Spectrophotometric estimation of purlifloxacin in bulk and pharmaceutical dosage form by UV spectrophotometry, Drug Invention Today, 2010, vol. 2, no. 10, pp. 454–456.
10. Arjunan, M., Al-Salamah, A.A., and Amuthan, M., Prevalence and antibiotics susceptibility of uropathogens in patients from a rural environment, Tamilnadu, Am. J. Infect. Dis., 2010, vol. 6, no. 2, p. 29.
11. Elsea, S., Osheroff, N., and Nitiss, J., Cytotoxicity of quinolones toward eukaryotic cells. Identification of topoisomerase II as the primary cellular target for the quinolone CP-115,953 in yeast, J. Biol. Chem., 1992, vol. 267, no. 19, pp. 13150–13153.
12. Robicsek, A., Jacoby, G.A., and Hooper, D.C., The worldwide emergence of plasmid-mediated quinolone resistance, Lancet Infect. Dis., 2006, vol. 6, no. 10, pp. 629–640.
13. Shi, R., Zhang, J., Li, C., Kazumi, Y., and Sugawara, I., Emergence of ofloxacin resistance in Mycobacterium tuberculosis clinical isolates from China as determined by gyrA mutation analysis using denaturing high-pressure liquid chromatography and DNA sequencing, J. Clin. Microbiol., 2006, vol. 44, no. 12, pp. 4566–4568.
14. Stevenson, J.E., Gay, K., Barrett, T.J., Medalla, F., Chiller, T.M., and Angulo, F.J., Increase in nalidixic acid resistance among non-typhi Salmonella enterica isolates in the United States from 1996 to 2003, Antimicrob. Agents Chemother., 2007, vol. 51, no. 1, pp. 195–197.
15. Deguchi, T., Fukuoka, A., Yasuda, M., Nakano, M., Ozeki, S., Kanematsu, E., Nishino, Y., Ishihara, S., Ban, Y., and Kawada, Y., Alterations in the GyrA subunit of DNA gyrase and the ParC subunit of topoisomerase IV in quinolone-resistant clinical isolates of Klebsiella pneumoniae, Antimicrob. Agents Chemother., 1997, vol. 41, no. 3, pp. 699–701.
16. Brisse, S., Milatovic, D., Fluit, A.C., Verhoef, J., and Schmitz, F.J., Epidemiology of quinolone resistance of Klebsiella pneumoniae and Klebsiella oxytoca in Europe, Eur. J. Clin. Microbiol. Infect. Dis., 2000, vol. 19, no. 1, pp. 64–68.
17. Chen, F.J., Lauderdale, T.L., Ho, M., and Lo, H.J., The roles of mutations in gyrA, parC, and ompK35 in fluoroquinolone resistance in Klebsiella pneumoniae, Microb. Drug Resist. (Larchmont, NY), 2003, vol. 9, no. 3, pp. 265–271.
18. Brisse, S., Milatovic, D., Fluit, A.C., Verhoef, J., Martin, N., Scheuring, S., Köhrer, K., and Schmitz, F.-J., Comparative in vitro activities of ciprofloxacin, clinafloxacin, gatifloxacin, levofloxacin, moxifloxacin, and trovafloxacin against Klebsiella pneumoniae, Klebsiella oxytoca, Enterobacter cloacae, and Enterobacter aerogenes clinical isolates with alterations in GyrA and ParC proteins, Antimicrob. Agents Chemother., 1999, vol. 43, no. 8, pp. 2051–2055.
19. Minarini, L.A.R. and Darini, A.L.C., Mutations in the quinolone resistance-determining regions of gyrA and parC in enterobacteriaceae isolates from Brazil, Braz. J. Microbiol., 2012, vol. 43, pp. 1309–1314.
20. Edgar, R.C., MUSCLE: multiple sequence alignment with high accuracy and high throughput, Nucleic Acids Res., 2004, vol. 32, no. 5, pp. 1792–1797.
21. Tamura, K., Peterson, D., Peterson, N., Stecher, G., Nei, M., and Kumar, S., MEGA5: molecular evolutionary genetics analysis using maximum likelihood, evolutionary distance, and maximum parsimony methods, Mol. Biol. Evol., 2011, vol. 28, no. 10, pp. 2731–2739.
22. Shon, A.S., and Russo, T.A., Hypervirulent Klebsiella pneumoniae: the next Superbug? Future Microbiol., 2012, vol. 7, no. 6, pp. 669–671.
23. Ghafourian, S., bin Sekawi, Z., Sadeghifard, N., Mohebi, R, Neela, V.K., Maleki, A., Hematian, A., Rahbar, M., Raftari, M., and Ranjbar, R., The prevalence of ESBLs producing Klebsiella pneumoniae isolates in some major hospitals, Iran, Open Microbiol. J., 2011, vol. 5, p. 91.
24. Zhao, W., Chiuman, W., Lam, J.C., McManus, S.A., Chen, W., Cui, Y., Pelton, R., Brook, M.A., and Li, Y., DNA aptamer folding on gold nanoparticles: from colloid chemistry to biosensors, J. Am. Chem. Soc., 2008, vol. 130, no. 11, pp. 3610–3618.
25. Ranjbar, R., Haghi-Ashtiani, M., Jafari, N.J., and Abedini, M., The prevalence and antimicrobial susceptibility of bacterial uropathogens isolated from pediatric patients, Iran. J. Public Health, 2009, vol. 38, no. 2, pp. 134–138.
26. Terstappen, G.C., and Reggiani, A., In silico research in drug discovery, Trends Pharmacol. Sci., 2001, vol. 22, no. 1, pp. 23–26.
27. Bleumin, D., Cohen, M.J., Moranne, O., Esnault, V.L., Benenson, S., Paltiel, O., Tzukert, K., Mor-Yosef Levi, I., Ben-Dov, I.Z., Levi, R., Bloch, A., and Haviv, Y.S., Carbapenem-resistant Klebsiella pneumoniae is associated with poor outcome in hemodialysis patients, J. Infect., 2012, vol. 65, no. 4, pp. 318–325.
28. Fu, Y., Zhang, W., Wang, H., Zhao, S., Chen, Y., Meng, F., Zhang, Y., Xu, H., Chen, X., and Zhang, F., Specific patterns of gyrA mutations determine the resistance difference to ciprofloxacin and levofloxacin in Klebsiella pneumoniae and Escherichia coli, BMC Infect. Dis., 2013, vol. 13, no. 1, pp. 8–14.
29. Vashist, J., Kapoor, R., Kapil, A., Yennamalli, R., Subbarao, N., and Rajeswari, M.R., Interaction of nalidixic acid and ciprofloxacin with wild type and mutated quinolone-resistance-determining region of DNA gyrase A, Ind. J. Biochem. Biophys., 2009, vol. 46, no. 2, pp. 147–153.
30. Monera, O.D., Sereda, T.J., Zhou, N.E., Kay, C.M., and Hodges, R.S., Relationship of sidechain hydrophobicity and α-helical propensity on the stability of the single-stranded amphipathic α-helix, J. Peptide Sci., 1995, vol. 1, no. 5, pp. 319–329.
31. Rattan, A., Mechanisms of resistance to fluoroquinolones, Natl. Med. J. India, 1999, vol. 12, pp. 162–164.
32. Weigel, L.M., Steward, C.D., and Tenover, F.C., GyrA mutations associated with fluoroquinolone resistance in eight species of enterobacteriaceae, Antimicrob. Agents Chemother., 1998, vol. 42, no. 10, pp. 2661–2667.
33. Osman, F.G., Pharmacophore Perception, Development, and Use in Drug Design, California, USA: International University Line, 2000, vol 2.
34. Terstappen, G.C., and Reggiani, A., In silico research in drug discovery, Trends Pharmacol. Sci., 2001, vol. 22, no. 1, pp. 23–26.